When evaluating the current available data, it is important to note that the majority of published trials have excluded patients who are ALCL, ALK-positive as these patients have a superior outcome with CHOP and CHOP-like regimens as opposed to other PTCL subtypes. Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.